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Abstract
Inflammatory breast cancer (IBC) is the most lethal form of locally advanced breast cancer known. IBC carries a guarded
prognosis primarily due to rapid onset of disease, typically within six months, and the propensity of tumor emboli to invade
the dermal lymphatics and spread systemically. Although the clinical manifestations of IBC have been well documented,
until recently little was known about the genetic mechanisms underlying the disease. In a comprehensive study aimed at
identifying the molecular mechanisms responsible for the unique IBC phenotype, our laboratory identified overexpression
of RhoC GTPase in over 90% of IBC tumors in contrast to 36% of stage-matched non-IBC tumors. We also demonstrated
that overexpression of RhoC GTPase in human mammary epithelial (HME) cells nearly recapitulated the IBC phenotype
with regards to invasion, motility and angiogenesis. In the current study we sought to delineate which signaling pathways
were responsible for each aspect of the IBC phenotype. Using well-established inhibitors to the mitogen activated protein
kinase (MAPK) and phosphatidylinositol-3 kinase (PI3K) pathways. We found that activation of the MAPK pathway was
responsible for motility, invasion and production of angiogenic factors. In contrast, growth under anchorage independent
conditions was dependent on the PI3K pathway.
Abbreviations: ELISA – enzyme linked immunoabsorbant assay; FBS – fetal bovine serum; FGF2 – basic fibroblast growth
factor; FGF-BP – fibroblast growth factor binding protein; HME – human mammary epithelial; IBC – inflammatory
breast cancer; IGFBP-rP – insulin-like growth factor binding protein related protein; IL – interleukin, LABC – locally
advanced breast cancer; MAPK – mitogen activated protein kinase; MEM – minimal essential medium; MTT – 3-[4,5-
Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; PI3K – phosphatidylinositol-3 kinase; TCA – tricholoracetic acid;
VEGF – vascular endothelial growth factor
Introduction
Inflammatory breast cancer (IBC) is a phenotypically dis-
tinct form of locally advanced breast cancer (LABC) that
has a propensity to invade, grow and spread in the dermal
lymphatics of the skin overlying the breast [1–3]. It is the
ability of the tumor emboli to invade and block the dermal
lymphatics that leads to its poor prognosis [1–4].
Although the clinical manifestations of IBC have been
well documented in the literature, until recently little was
known about the molecular mechanisms involved in con-
ferring the unique IBC phenotype. In an effort to identify
genetic alterations involved in determining the IBC phe-
notype, our laboratory isolated two genes that were con-
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sistently and concordantly altered in IBC compared with
stage-matched non-IBC tumors [5]. RhoC GTPase, was
found to be over-expressed in 90% of IBC tumors versus
36% of the stage-matched controls.
RhoC GTPase is a member of the Ras-superfamily of
small GTP binding proteins and is primarily responsible
for re-organization of the actin cytoskeleton leading to the
formation of lamellipodia and fillipodia resulting in cellu-
lar motility [6–13]. Transfection of the RhoC homologue,
RhoB, into Ras-transformed NIH3T3 cells leads to increased
focus formation suggesting a role for the Rho proteins as a
transforming oncogene or as a metastasis gene [14]. Simi-
larly, our laboratory has demonstrated that RhoC transfected
HME cells become highly motile and invasive, grow under
anchorage independent conditions, produce angiogenic fac-
tors, and are tumorigenic and metastatic when orthotopically
implanted into nude mice [15–17].
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These in vitro data have additional clinical significance
as RhoC overexpression is associated with the transition
to metastatic disease in other cancers [18–20]. It has been
proposed that Rho proteins act through and potentiate sig-
naling via the c-Jun kinase/stress activated protein kinase
(JNK/SAPK) and mitogen activated protein kinase (MAPK)
pathway (reviewed by Takai et al. [21]). Evidence from other
laboratories suggest that Rho proteins can signal through
both the MAPK pathway as well as the phosphoinositol-3
kinase (PI3K) pathway, while cdc42 and Rac1 are associ-
ated with the JNK/SAPK pathway [22–25]. Furthermore, it
has been demonstrated that in certain cell types, the MAPK
pathway is involved in signaling and the production of an-
giogenic factors while the PI3K pathway is involved in
growth and survival [26–33].
In the present study we set out to determine the major
pathways involved in RhoC signaling in IBC. Specifically,
we attempted to determine which pathways and cascades
were involved in conferring specific aspects of the RhoC-
induced phenotype. Many of the published studies that
describe the signal transduction pathways involved in Rho
signaling were performed in transfected NIH3T3 cells, thus
our study focused on the RhoC signaling pathways spe-
cific to IBC and HME cells. We treated HME-RhoC stable
transfectants, control HME-β-galactosidase (HME-β-gal)
transfectants or the SUM149 IBC cell line with C3 exo-
transferase (a specific inhibitor of Rho proteins), a variety
of MAPK inhibitors, or a PI3K inhibitor and assayed them
for specific biological functions. The inhibitors were used at
concentrations that would inhibit signal transduction without
affecting cellular viablility. We found that the PI3K pathway
was involved in anchorage independent growth and survival,
while multiple arms of the MAPK pathway were involved
in motility and invasion, and that p38 is a downstream mod-
ulator in the production of angiogenic factors. These data
provide significant new insight as to how overexpression of




Cell lines were maintained under defined culture condi-
tions for optimal growth in each case [34–36]. Briefly,
human mammary epithelial (HME) cells were immortal-
ized with human papilloma virus E6/E7 [37] and grown
in 5% fetal bovine serum (FBS; Sigma Chemical Co.,
St. Louis, Missouri) supplemented Ham’s F-12 medium
(JRH BioSciences, Lenexa, Kansas) containing insulin, hy-
drocortisone, epidermal growth factor, and cholera toxin
(Sigma Chemical Co.). Stable HME transfectants containing
either the human wild-type RhoC GTPase or control β-
galactosidase genes were produced and maintained in the de-
scribed medium supplemented with 100 µg/ml hygromycin
(LifeScience Technologies) as previously published [15–
17]. The SUM149 cell line was developed from a primary
IBC tumor and grown in 5% FBS supplemented Ham’s F-12
medium containing insulin and hydrocortizone. The HME
cells were characterized as being keratin 19 positive, ensur-
ing that they are from the same differentiation lineage as the
SUM149 IBC tumor cell line [5].
Cells actively growing in culture were treated with
MAPK inhibitors, 2.0 µM PD98059, 1.5 µM U0126,
1.5 µM SKF86002, or 1.5 µM SB220025 (all obtained
from Calbiochem, San Diego, California) 24 h prior to as-
says and treated everyday with fresh inhibitor until the end
of the assay. Treatment of cells with 2.5 µM LY294002
(Calbiochem), a PI3K inhibitor, was performed in the same
manner as described for the MAPK inhibitors. These con-
centrations were below the IC50 of the compounds to avoid
direct cell toxicity to allow for meaningful biological assays.
Western blot analysis
Proteins were harvested from cell cultures using RIPA buffer
(1× PBS, 1% Nonidet P-40, 0.5% sodium deoxycholate,
0.1% SDS, 0.1 mg/ml PMSF, 1 mM sodium orthovanadate
and 0.3 mg/ml aprotinin; Sigma Chemical Co.). Ten µg
aliquots were mixed with Laemelli buffer, heat denatured
for 3 min, separated by SDS-PAGE, and transferred to ni-
trocellulose. Non-specific binding was blocked by overnight
incubation with 2% powdered milk in tris-buffered saline
with 0.05% Tween-20 (Sigma Chemical Co.). Immobilized
proteins were probed using antibodies specific for total
MAPK proteins, the membranes were then stripped and
reprobed for the phosphorylated form of the MAPK protein.
Specifically, p38/pp38, pJNK/ppJNK, and pErk/ppErk (Cell
Signaling Technologies, Beverly, Massachusettes). Pro-
tein bands were visualized by ECL (Amersham-Pharmacia
Biotech, Piscataway, New Jersey).
C3 exotransferase treatment
Active C3 exoenzyme was introduced into the HME, HME-
β-gal, HME-RhoC, and SUM149 cells using a method based
on liposome encapsulation and membrane fusion, which we
have termed lipoporation [16]. Briefly, cells were grown in
6-well plates until reaching a confluence of 40–50% and the
medium replaced with fresh medium. Three micrograms of
human recombinant C3 exotransferase (Cytoskeleton Inc.,
Denver, Colorado) was combine with FuGeneTM 6 trans-
fection reagent (Roche-Boehringer Mannheim) and added to
the cultures. As controls either an equal quantity of human
recombinant tubulin or FuGeneTM 6 alone were added to cell
cultures. The cells were incubated for 2 days at 37 ◦C, at
which time cell-conditioned medium was harvested. Pres-
ence of the intracellular C3 exoenzyme was confirmed by
visualizing the rhodamine-tagged protein using fluorescent
microscopy. The efficiency and activity of both the trans-
fected and lipoporated C3 exoenzyme were confirmed by a
quantitative ADP-ribosylation assay [38].
The efficiency of in vivo ADP-ribosylation of RhoC GT-
Pase by C3 exotransferase was determined as previously
described [16]. Active C3 exotransferase was efficiently in-
troduced into HME-β-gal, HME-RhoC, and SUM149, as
described above. Cells were collected 48 h later, washed
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in medium, and pelleted. The cells were lysed in 20 mM
HEPES pH 8.0 (Sigma Chemical Co.) by 3 repeated
freeze/thaw cycles. Cell lysates (10 µg) were combined with
50 ng/ml C3 exotransferase and 5×106 cpm (with a specific
activity of 1×106 cpm/µl) [32P]NAD (Amersham) in ADP-
ribosylation buffer (20 mM HEPES, pH 8.0, 1 mM MgCl2,
1 mM AMP and thymadine, Sigma Chemical Co.), and in-
cubated for 30 min at 37 ◦C. TCA-percipitable material was
then recovered and radioactivity was counted on a Packard
scintillation counter.
Growth assays
Monolayer culture growth rate was determined as
previously described [39] by conversion of MTT (3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide;
Sigma Chemical Co.) to a water insoluble formazon by vi-
able cells. Three thousand cells in 200 µl medium were
plated in 96-well plates and grown under normal conditions.
Cultures were assayed at 0, 1, 2, 3, 5 and 7 days by the
addition of 40 µl 5 mg/ml MTT and incubating for 1 h at
37 ◦C. The time points of the assay were chosen to suffi-
ciently discern any effect that the inhibitors may have on cell
viability, which may affect the outcomes of the phenotypic
experiments. The MTT containing medium was aspirated
and 100 µl DMSO (Sigma Chemical Co.) added to lyse the
cells and solublize the formazon. Absorbance values of the
lysates were determined on a Dynatech MR 5000 microplate
reader at 540 nm.
For anchorage independent growth assays, a 2% stock
of sterile low-melt agarose was diluted 1:1 with 2× MEM.
Further dilution to 0.6% agarose was made using 10% FBS
supplemented Ham’s F-12 medium complete with growth
factors, and 1 ml was added to each well of a six-well plate
as a base-layer. The cell layer was then prepared by diluting
agarose to 0.3% and 0.6% with 103 cells in 2.5% FBS sup-
plemented Ham’s F-12/1.5 ml/well. Colonies greater than
or equal to 100 µ in diameter were counted after a 3-week
incubation at 37 ◦C in a 10% CO2 incubator.
Random motility assay
Random motility was determined using a gold-colloid assay
[40]. Gold-colloid (Sigma Chemical Co.) was layered onto
glass coverslips and placed into 6-well plates. Cells were
plated onto the coverslips and allowed to adhere for 1 h
at 37 ◦C in a CO2 incubator (12 500 cells/3 ml in serum-
free medium). To stimulate the cells, the serum-free medium
was replaced with 5% FBS containing Ham’s F-12 supple-
mented with growth factors and allowed to incubate for 3 h at
37 ◦C. The medium was aspirated and the cells fixed using
2% gluteraldehyde (Sigma Chemical Co.). The coverslips
were then mounted onto glass microscope slides and areas
of clearing in the gold-colloid corresponding to phagokinetic
cell tracks counted.
Invasion assay
The invasion assay was performed as previously described
with minor modification [39]. A 10 µl aliquot of 10 mg/ml
Matrigel (Becton Dickenson, Bedford, Massachusetts) was
spread onto a 6.5 mm Transwell filter with 8 µm pores
(Costar, Corning, New York) and air dried in a laminar
flow hood. Once dried, the filters were reconstituted with
a few drops of serum-free medium. The lower chamber of
the Transwell was filled with either serum-free or serum
containing media. Cells were harvested and resuspended in
serum-free medium with 0.1% BSA at a concentration of
3.75×105 cells/ml and 0.5 ml was added to the top chamber.
The chambers were incubated for 24 h at 37 ◦C in a 10%
CO2 incubator. The cell suspension was aspirated and excess
Matrigel removed from the filter using a cotton swab. The
filters were then cut away from the Transwell assembly and
fixed with methanol, gel side down, to a glass microscope
slide. The fixed filters were stained with hematoxylin and
eosin, and the cells on the entire filter were counted at a
40×-magnification individually by two investiagtors. These
cells were assumed to have invaded through the Matrigel and
filter. The number of cells that had invaded in the serum-free
containing lower chambers was considered background and
this number was subtracted from the number of cells that had
invaded in response to the serum-containing medium.
Quantitation of vascular endothelial growth factor
Levels of soluble cytokines and chemokines were deter-
mined from cell-conditioned media. Cells were incubated in
normal growth medium for four days. The cell-conditioned
media was harvested, centrifuged for 5 min at 2,500 rpm
and divided into 1 ml aliquots. The Quantikine human vas-
cular endothelial growth factor (hVEGF; R&D Systems,
Minneapolis, Minnesota) were used to measure protein lev-
els of the 165 amino acid species of hVEGF. The enzyme
linked immunoabsorbant assay (ELISA) was performed per
the manufacturers recommendations.
Results
C3 exotransferase inhibition of RhoC GTPase
In a previous study we demonstrated that inhibition of RhoC
GTPase activity by C3 exotransferase treatment led to de-
creased production of angiogenic factors [16, 17]. In order
to demonstrate that the other phenotypic changes seen in
the HME-RhoC transfectants are indeed due to RhoC ex-
pression, we treated the cells with C3 exotransferase. C3
exotransferase is not a specific inhibitor of RhoC per se,
but a specific inhibitor of Rho proteins (reviewed in [41]).
C3 has been demonstrated to have an affinity for RhoC and
affects the formation of actin filaments in vivo [42]. Given
that the untransfected HME, the HME-β-galactosidase con-
trol transfectants, and the HME-RhoC transfected cells were
all derived from the same culture, they are likely to share the
same distribution of Rho proteins, except for RhoC. There-
fore, main changes of phenotype produced by C3 treatment
would be ascribed to C3 induced changes in RhoC GTPase
activity.
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Table 1. Comparison of monolayer population doubling time and anchorage indepen-
dent growth of untreated and C3 treated HME, HME transfectants and SUM149 IBC
cell lines. Despite treatment of the cells with C3, monolayer population doubling time
was not affected. In contrast, the ability of the RhoC expressing HME and SUM149 cells
to grow under anchorage independent conditions was significantly reduced (∗P = 0.01,
∗∗P = 0.001).
Population doubling time Anchorage independent growth
(hours) (number of cholonies)
Untreated C3 Treated Untreated C3 Treated
HME 34 h 36 h 0 ± 0 0 ± 0.1
HME-β-gal 35 h 34 h 5 ± 0.8 17 ± 7.5
HME-RhoC 33 h 36 h 102 ± 5.4 40 ± 13.6∗∗
SUM149 39 h 39 h 75 ± 4.9 47 ± 3.3∗
Active C3 exotransferase was introduced into the cells
using a liposome mediated method termed lipoporation [16].
As shown in Table 1, the population doubling time of all the
cell lines tested was not significantly affected by C3 treat-
ment. However, the ability of the HME-RhoC transfectants
and the SUM149 IBC cell line to grow under anchorage
independent conditions, a hallmark of malignant transfor-
mation, was significantly reduced. In contrast, C3 treatment
of the HME untransfected or the HME-β-gal control did not
result in any changes in their ability to grow in soft agar. The
monolayer growth rate was not influenced by transfection or
RhoC expression, as the HME-RhoC transfectants did not
differ from the untransfected or control transfected HME
counterparts, or by C3 treatment so, these data suggest that
RhoC confers the ability to HME-RhoC cells to grow under
anchorage independent conditions.
As demonstrated in Figure 1A, C3 treatment significantly
reduced HME-RhoC and SUM149 IBC motility in a ran-
dom colloidal gold assay. The HME-β-galactosidase control
transfectants were unaffected by C3 treatment. Similarly, the
ability of the HME-RhoC and SUM149 cells to invade a
Matrigel coated filter in response to a chemoattractant was
significantly reduced after C3 treatment (Figure 1B).
The activity of the C3 exotransferase was confirmed by
measuring the efficiency of in vivo ADP-ribosylation. As
shown in Figure 1C, in comparison with their non-C3 treated
counterparts, all the C3 treated cell lines had a significant
reduction in the levels of available sites that could be ADP-
ribosylated in the in vitro assay. Specifically, the C3-treated
HME-RhoC and SUM149 cells had a 2-fold decrease in
the number of ADP-ribosylated sites compared to the non-
transfected controls. These data indicate that at least half of
the Rho proteins have been ADP-ribosylated in vivo, and
therefore inhibited by C3 exotransferase. Taken together,
these data demonstrate that expression and activity of RhoC
GTPase is responsible for conferring the ability to grow un-
der anchorage independent conditions, and the production of
a motile and invasive cell.
Inhibition of anchorage independent growth by the
LY294002 PI3K inhibitor
To determine whether the PI3K or the MAPK pathways
were involved in RhoC signaling, the cells were treated with
either LY294002 (a potent PI3K inhibitor) or PD98059 (a
general MAPK inhibitor that blocks all arms of the MAPK
pathway). To avoid confounding effects due to direct cy-
totoxicity, we chose concentrations of the inhibitors that
inhibited signal transduction but were not cytotoxic. The
cells were treated 48 h prior to plating in 0.6% soft agar and
fresh medium containing each of the inhibitors was layered
onto the soft agar daily. The MCF10AT c1 cell line, with
a constituitvely active Ras was used as a positive control
[43]. The ability of the HME-RhoC and SUM149 cells to
form colonies in 0.6% soft agar was significantly reduced
by treatment with the PI3K inhibitor (Figure 2). In contrast,
treatment with the general MAPK inhibitor PD98059 had
little effect on the colony number. The reduction in colony
formation was not due to a significant change in the pop-
ulation doubling time of the cells treated with LY294002,
as determined by an MTT monolayer growth assay per-
formed on cells treated long-term with the inhibitors (data
not shown). These data indicate the PI3K pathway, and not
the MAPK pathway is involved in RhoC conferring the abil-
ity of the cells to survive and form colonies under anchorage
independent conditions.
MAPK status in cell lines after inhibitor treatment
In order to determine which arms of the MAPK pathway
were involved in the different aspects of the RhoC-induced
phenotype, the cells were treated with a variety of MAPK
inhibitors that affect different points of the pathway. The
general MAPK inhibitor PD98059 effects the MAPK path-
way at 2 distinct, points; (1) MEKK-1 (which activates p38
and MEK1 & 2, and therefore ERK1 & 2), and (2) directly at
MEK1 & 2. The inhibitor U0126 specifically inhibits MEK1
& 2 activation. The inhibitors SKF86002 and SB22025 are
inhibitors of p38 activation and of p38 itself, respectively. As
demonstrated in Figure 3, all cell lines expressed p38, ERK
(p42/p44), and JNK/SAPK. However, none of the untreated
cell lines (A) expressed activated phospho-JNK/SAPK, sug-
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Figure 1. Comparison of the average area of migration in a colloidal gold motility assay by control HME-β-gal and RhoC overexpressing mammary cells
after treatment with C3 exotransferase. Treatment of cells with C3 exoenzyme significantly reduced the motile ability of the RhoC overexpressing cells
HME-RhoC and SUM149. Similarly, as demonstrated in panel B, the invasive capabilities of the RhoC overexpressing cells were also significantly reduced
after C3 treatment as determined in a Matrigel invasion assay. To determine the extent of Rho inhibition by C3 exotransferase, an in vitro ADP-ribosylation
assay was performed (panel C). The number of ADP-ribosylated targets was greatly reduced in the HME-RhoC and SUM149 cells, thus indicating that C3
exotransferase treatment had effectively blocked the Rho targets within those cells.
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Figure 2. Anchorage independent growth in 0.6% soft agar after treatment with either the PI3K inhibitor LY294002 or the general MAPK inhibitor
PD98059. The ability of the RhoC overexpressing cells HME-RhoC and SUM149 was significantly reduced after treatment with the LY294002, but not
with PD98059. These data suggests that RhoC-mediated anchorage independent growth, is signaled through the PI3K and not the MAPK pathway in these
mammary cells.
Figure 3. Western blot analysis of basal and phosphorylated (activated) levels of different arms of the MAPK pathway before (A) and after inhibitor
treatment with SKF86002 (B), PD98059 (C), U0126 (D), or C3 exotransferase (E). All the cell lines tested expressed ERK (p42/p44), JNK/SAPK, and
p38. However, none of the untreated cell lines (A) expressed activated phospho-JNK/SAPK, suggesting that only pp38 and phospho-ERK are involved
in RhoC signal transduction. Each set of Western blots looking at p38, JNK/SAPK and ERK were performed separately on the same cell lysates. Each
individual blot in the set (i.e. total protein versus the phosphorylated form of that protein) was the same blot stripped and re-probed.
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gesting that only pp38 and phospho-ERK are involved in
RhoC signal transduction. Each set of Western blots looking
at p38, JNK/SAPK and ERK were performed separately on
the same cell lysates. Each individual blot in the set (i.e.,
total protein versus the phosphorylated form of that pro-
tein) was the same blot stripped and re-probed. Each set of
Western blots looking at p38, JNK/SAPK and ERK were
performed separately on the same cell lysates. Each set of
Western blots compares total protein versus the phospho-
rylated form of that protein of the same blot. Treatment of
the cells for 24 h with SKF86002 (B), PD98059 (C), U0126
(D), or C3 exotransferase (E), led to a decrease in the levels
of the active phosphorylated form of the target protein(s),
while the basal levels remained unchanged. Interestingly, C3
treatment of the cells lead to increased phosphorylation of
JNK/SAPK.
Effect of inhibition of MAPK on motility and invasion
Because of the postulated relationship between Rho-induced
motility and Ras activation of the MAPK pathway, we
set out to understand how are the MAPK signaling cas-
cades are involved in Rho-modulated motility and invasion.
To accomplish this we treated the cells with the various
MAPK inhibitors described above. The cells were treated
with the MAPK inhibitors 48 h prior to assessing motility
and invasion. No significant decrease in population doubling
time was observed for the cells treated with inhibitors, as
determined over a seven-day assay (data not shown).
As demonstrated in Figure 4A, all of the MAPK in-
hibitors had a significant (P = 0.01) effect on the motility
of the HME-RhoC and SUM149 cell lines. The areas of the
phagokinetic tracks were reduced to nearly the level of the
HME-β-gal control cell line, which was unaffected by any
of the MAPK inhibitors. Since all of the MAPK inhibitors
had an effect on the motility of the cells, this suggested
that multiple arms of the MAPK pathway are involved in
RhoC mediated motility. Motility of the MCF10AT c1 posi-
tive control cell line that has a constituatively active Ras was
also affected by all four of the MAPK inhibitors, although
the motility of these cells is much reduced compared to the
HME-RhoC and SUM149 cells.
Next, we concentrated on the cells ability to invade
through a Matrigel coated filter (Figure 4B). The invasive
capabilities of the cells are described as fold-increase in
invasion over untransfected HME controls. Treatment with
all four of the MAPK inhibitors reduced the invasive ca-
pabilities of the HME-RhoC and SUM149 cell lines. The
HME-β-gal control cells were not significantly affected, by
the other MAPK inhibitors. The invasive capabilities of
the MCF10AT c1 cells were the same as the HME-β-gal
control cells, and were likewise unaffected by the MAPK
inhibitors. When cells were treated with a combination of the
LY294002 and PD98059 inhibitors, the level of inhibition
was similar to that of the PD98059 inhibitor alone (data not
shown), suggesting that the PI3K pathway is not involved in
either motility or invasion.
Taken together, these data suggest that RhoC induced
motility and invasion is mediated to a significant extent by
the p38 and ERK arms of the MAPK pathway. This is shared
with Ras alone induced motility, but active Ras is not suffi-
cient to produce an invasive phenotype in the MCF10A cells.
In all these experiments the concentrations of inhibitors used
did not effect cell doubling times or cell viability.
VEGF production after inhibition of the MAPK pathway
In a previous study, we demonstrated that RhoC overex-
pression leads to increased production of angiogenic factors,
particularly vascular endothelial growth factor (VEGF) [16,
17]. Since VEGF production was significantly increased in
RhoC expressing breast cells, and considering its importance
in as an angiogenic factor, VEGF expression was the log-
ical endpoint to study after inhibitor treatment. Treatment
of the mammary cells with the different MAPK inhibitors
resulted in decreased VEGF production by the HME-RhoC
and SUM149 IBC cell lines (Figure 5). The greatest re-
duction in VEGF production was seen when the cells were
treated with the inhibitor SB22025, which prevents p38
activation. Treatment with the inhibitor SKF86002, an in-
hibitor of phosho-p38 activity, resulted in the second greatest
decrease in VEGF production. Taken together, these data
suggest that activation of the p38 arm of the MAPK pathway
is responsible for production of VEGF simultaneously by
RhoC overexpression.
Discussion
The highly invasive and metastatic phenotype of IBC is one
of the hallmarks of its unique clinical manifestations and the
major cause of the poor outcome of many patients who are
diagnosed with IBC. In a previous set of studies, our labo-
ratory identified RhoC GTPase to be overexpressed in IBC
and responsible for anchorage independent growth, cellular
motility and invasion, and production of angiogenic factors.
In the current study, we begin to delineate the signaling
pathways responsible for each aspect of the RhoC-mediated
phenotype. We hypothesized that for RhoC GTPase to
achieve diverse phenotypic attributes, cell signaling must
take place through several signal transduction pathways. We
utilized specific inhibitors of different points of the PI3K and
MAPK pathways, an approach which has proven successful
in similar previous studies [44, 45].
The MAPK pathway has been previously implicated in
Ras and RhoA signaling, while the JNK/SAPK pathway
has been shown to be mediated by Rac1 and cdc42 sig-
naling, and all have been shown to use the PI3K pathway
(reviewed in [46, 47]). These pathways, depending on cell
type, have been attributed to participate in growth/survival
and motility (reviewed in [29]). However, the signal trans-
duction pathway(s) utilized by RhoC during growth, motility
and invasion has not been described in any cell type. In
the current study we examined RhoC signal transduction
in the SUM149 IBC and HME-RhoC breast cell lines. Be-
cause RhoC appears to be a major determinant of a clinically
well-defined mammary cancer metastatic phenotype it is es-
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Figure 4. Effects on motility and invasion of RhoC overexpressing cells after treatment with PD98059, U0126 or the p38 inhibitor SB220225. Panel A
demonstrates a significant decrease in the motility of the RhoC overexpressing HME-RhoC and SUM149 cells treated with the various MAPK inhibitors.
Similarly, the ability of these cells to invade through a Matrigel coated filter was also significantly reduced after treatment with the MAPK inhibitors (panel
B). These data suggest that RhoC mediated motility and invasion is mediated through the MAPK pathway, to a large extent through activated p38.
pecially relevant to understand how RhoC elicits multiple
actions in breast tissue.
Using MAPK and PI3K inhibitors at concentrations be-
low cytotoxic and cytostatic levels, we have determined
that the PI3K pathway is involved in the ability of RhoC
overexpressing cells to grow under anchorage independent
conditions without effecting monolayer growth. We also
determined that signaling through the MAPK pathway is in-
volved in motility, invasion and the production of angiogenic
factors. Specifically, we found that the ERK and p38 arms of
the MAPK signaling complex are involved in motility and
invasion, as no one inhibitor of the individual arms com-
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Figure 5. The effect of MAPK inhibitors on the production and secretion of the pro-angiogenic molecule vascular endothelial growth factor (VEGF).
Production of VEGF by the HME-RhoC and SUM149 cell lines were significantly reduced when the cells were treated with the p38 inhibitors SB220225
or SKF86002. Taken together, these data suggest that activation of the p38 arm of the MAPK pathway is responsible for production of VEGF simultaneously
by RhoC overexpression.
pletely blocked motility of the HME-RhoC or SUM149 IBC
cell lines. In addition, although it is expressed, we know that
JNK/SAPK does not appear to be involved given that it is
not phosphorylated or active in any of the breast lines (IBC
or HME) studied.
Previous experiments have demonstrated that the var-
ious signal transduction pathways have diverse effects in
different cell types activated by a variety of stimuli. For
example in Schwann cells, PI3K activation by Rac1 lead-
ing to lamellipodia formation and motility has been shown
to occur upon stimulation by insulin-like growth factor-I
[25]. Whereas stimulation of adipocytes with insulin leads
activation of the PI3K pathway and Rho-mediated glucose
uptake [48]. In support of our data, Amundadottir and
Leder [49] demonstrated that regardless of the oncogene in-
volved in transformation, the PI3K pathway was involved
in conferring anchorage independent growth to transformed
mammary epithelial cells. They also demonstrated that an-
chorage independent growth of mammary cells transformed
by Her2/neu, v-Ha-ras, and c-myc, could not be inhibited by
treatment with the MAPK inhibitor PD98059. Thus consis-
tent with our study of RhoC-expressing cells, it appears that
the PI3K pathway is exclusively involved in conferring an-
chorage independent growth, without involving the MAPK
pathway.
Several studies have demonstrated that activation of the
MAPK pathway can lead to cell migration and invasion of
fibroblasts, keratinocytes and endothelial cells [50–52]. Fur-
ther, it has been well documented that the Rho proteins can
activate the MAPK cascade stimulating various aspects of
cellular motility [29, 53–55]. Rac1 and cdc42 have been
shown to signal gene transcription through JNK/SAPK and
RhoA through p38, or when bound to fibronectin, ERK 1
& 2 [22, 53, 56, 57]. Akin to RhoA, we have made simi-
lar observations for RhoC, having demonstrated activation
of both p38 and ERK, but not JNK/SAPK, in IBC and
transfected HME cells. During motility, a dynamic interplay
between Rac1, cdc42 and Rho must occur to form lamellipo-
dia, fillipodia, focal adhesions, and stress fibers [7, 58, 59].
‘Cross-talk’ between these molecules results in reciprocal
activation of Rho with Rac1 and cdc42 [59–61]. Therefore,
each arm of the MAPK pathway may be involved in motility
and invasion during some point of the process.
In a previous study we demonstrated that levels of VEGF
was significantly elevated due to RhoC overexpression [16].
In support, other laboratories have demonstrated that expres-
sion of angiogenic factors is mediated by the p38 MAPK
cascade [26–28]. An increasing body of evidence suggests
that the mode of VEGF induction (i.e., MAPK vs. PI3K)
by activated H-ras is a cell-type specific process, with cells
of epithelial origin signaling more commonly through the
MAPK pathway and those cells of mesodermal origin utiliz-
ing the PI3K pathway [62]. Stimulation of a variety of breast
cancer cell lines with heregulin results in activation of p38
and subsequent upregulation of VEGF expression and se-
cretion [28]. Similarly, epidermal growth factor stimulation
of squamous cell carcinoma cell lines, results in activation
of both p38 and ERK, which in turn, leads to expression
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of fibroblast growth factor-binding protein (FGF-BP), a po-
tent angiogenic modulator [26]. Furthermore, it has been
suggested that Rho proteins and the p38-MAP kinase path-
way modulate IL-8 expression [63, 64]. IL-8 expression has
profound biological consequences: it is a potent angiogenic,
mitogenic and chemotactic factor in several malignancies in-
cluding breast and prostate cancer [65–69]. Still others have
suggested that FGF2, acting in an autocrine and paracrine
fashion, can induce IL-6 expression through p38. In future
studies we will determine whether IL-6, IL-8, and FGF2
production is also modulated by the p38 pathway in RhoC
overexpressing mammary cells.
In conclusion, we have begun to identify the differ-
ent signal transduction pathways involved in RhoC GTPase
driven phenotypes associated with highly metastatic inflam-
matory breast cancer. We specifically demonstrated that
anchorage independent growth is mediated via the PI3K
pathway. Induction of motility and invasion are mediated
through activation of the ERK and p38 arms of the MAPK
pathway, and the production of VEGF is mediated primarily
by p38 activation. This study provides new insight into the
signal transduction pathways of an aggressive disease medi-
ated by overexpression and activation of RhoC GTPase and
suggests new potential targets for therapeutic interventions
focused on the biological actions of RhoC.
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